Tag Archives: galaxy

#431559 Drug Discovery AI to Scour a Universe of ...

On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe.
The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.
Yes, this includes wow-the-stars-are-freaking-amazing-tonight drugs, but also the kinds of drugs that make us well again when we’re sick. The number of possible organic compounds with “drug-like” properties dwarfs the number of stars in the universe by over 30 orders of magnitude.
Next to this multiverse of possibility, the chemical configurations scientists have made into actual medicines are like the smattering of stars you’d glimpse downtown.
But for good reason.
Exploring all that potential drug-space is as humanly impossible as exploring all of physical space, and even if we could, most of what we’d find wouldn’t fit our purposes. Still, the idea that wonder drugs must surely lurk amid the multitudes is too tantalizing to ignore.
Which is why, Alex Zhavoronkov said at Singularity University’s Exponential Medicine in San Diego last week, we should use artificial intelligence to do more of the legwork and speed discovery. This, he said, could be one of the next big medical applications for AI.
Dogs, Diagnosis, and Drugs
Zhavoronkov is CEO of Insilico Medicine and CSO of the Biogerontology Research Foundation. Insilico is one of a number of AI startups aiming to accelerate drug discovery with AI.
In recent years, Zhavoronkov said, the now-famous machine learning technique, deep learning, has made progress on a number of fronts. Algorithms that can teach themselves to play games—like DeepMind’s AlphaGo Zero or Carnegie Mellon’s poker playing AI—are perhaps the most headline-grabbing of the bunch. But pattern recognition was the thing that kicked deep learning into overdrive early on, when machine learning algorithms went from struggling to tell dogs and cats apart to outperforming their peers and then their makers in quick succession.
[Watch this video for an AI update from Neil Jacobstein, chair of Artificial Intelligence and Robotics at Singularity University.]

In medicine, deep learning algorithms trained on databases of medical images can spot life-threatening disease with equal or greater accuracy than human professionals. There’s even speculation that AI, if we learn to trust it, could be invaluable in diagnosing disease. And, as Zhavoronkov noted, with more applications and a longer track record that trust is coming.
“Tesla is already putting cars on the street,” Zhavoronkov said. “Three-year, four-year-old technology is already carrying passengers from point A to point B, at 100 miles an hour, and one mistake and you’re dead. But people are trusting their lives to this technology.”
“So, why don’t we do it in pharma?”
Trial and Error and Try Again
AI wouldn’t drive the car in pharmaceutical research. It’d be an assistant that, when paired with a chemist or two, could fast-track discovery by screening more possibilities for better candidates.
There’s plenty of room to make things more efficient, according to Zhavoronkov.
Drug discovery is arduous and expensive. Chemists sift tens of thousands of candidate compounds for the most promising to synthesize. Of these, a handful will go on to further research, fewer will make it to human clinical trials, and a fraction of those will be approved.
The whole process can take many years and cost hundreds of millions of dollars.
This is a big data problem if ever there was one, and deep learning thrives on big data. Early applications have shown their worth unearthing subtle patterns in huge training databases. Although drug-makers already use software to sift compounds, such software requires explicit rules written by chemists. AI’s allure is its ability to learn and improve on its own.
“There are two strategies for AI-driven innovation in pharma to ensure you get better molecules and much faster approvals,” Zhavoronkov said. “One is looking for the needle in the haystack, and another one is creating a new needle.”
To find the needle in the haystack, algorithms are trained on large databases of molecules. Then they go looking for molecules with attractive properties. But creating a new needle? That’s a possibility enabled by the generative adversarial networks Zhavoronkov specializes in.
Such algorithms pit two neural networks against each other. One generates meaningful output while the other judges whether this output is true or false, Zhavoronkov said. Together, the networks generate new objects like text, images, or in this case, molecular structures.
“We started employing this particular technology to make deep neural networks imagine new molecules, to make it perfect right from the start. So, to come up with really perfect needles,” Zhavoronkov said. “[You] can essentially go to this [generative adversarial network] and ask it to create molecules that inhibit protein X at concentration Y, with the highest viability, specific characteristics, and minimal side effects.”
Zhavoronkov believes AI can find or fabricate more needles from the array of molecular possibilities, freeing human chemists to focus on synthesizing only the most promising. If it works, he hopes we can increase hits, minimize misses, and generally speed the process up.
Proof’s in the Pudding
Insilico isn’t alone on its drug-discovery quest, nor is it a brand new area of interest.
Last year, a Harvard group published a paper on an AI that similarly suggests drug candidates. The software trained on 250,000 drug-like molecules and used its experience to generate new molecules that blended existing drugs and made suggestions based on desired properties.
An MIT Technology Review article on the subject highlighted a few of the challenges such systems may still face. The results returned aren’t always meaningful or easy to synthesize in the lab, and the quality of these results, as always, is only as good as the data dined upon.
Stanford chemistry professor and Andreesen Horowitz partner, Vijay Pande, said that images, speech, and text—three of the areas deep learning’s made quick strides in—have better, cleaner data. Chemical data, on the other hand, is still being optimized for deep learning. Also, while there are public databases, much data still lives behind closed doors at private companies.
To overcome the challenges and prove their worth, Zhavoronkov said, his company is very focused on validating the tech. But this year, skepticism in the pharmaceutical industry seems to be easing into interest and investment.
AI drug discovery startup Exscientia inked a deal with Sanofi for $280 million and GlaxoSmithKline for $42 million. Insilico is also partnering with GlaxoSmithKline, and Numerate is working with Takeda Pharmaceutical. Even Google may jump in. According to an article in Nature outlining the field, the firm’s deep learning project, Google Brain, is growing its biosciences team, and industry watchers wouldn’t be surprised to see them target drug discovery.
With AI and the hardware running it advancing rapidly, the greatest potential may yet be ahead. Perhaps, one day, all 1060 molecules in drug-space will be at our disposal. “You should take all the data you have, build n new models, and search as much of that 1060 as possible” before every decision you make, Brandon Allgood, CTO at Numerate, told Nature.
Today’s projects need to live up to their promises, of course, but Zhavoronkov believes AI will have a big impact in the coming years, and now’s the time to integrate it. “If you are working for a pharma company, and you’re still thinking, ‘Okay, where is the proof?’ Once there is a proof, and once you can see it to believe it—it’s going to be too late,” he said.
Image Credit: Klavdiya Krinichnaya / Shutterstock.com Continue reading

Posted in Human Robots

#430854 Get a Live Look Inside Singularity ...

Singularity University’s (SU) second annual Global Summit begins today in San Francisco, and the Singularity Hub team will be there to give you a live look inside the event, exclusive speaker interviews, and articles on great talks.
Whereas SU’s other summits each focus on a specific field or industry, Global Summit is a broad look at emerging technologies and how they can help solve the world’s biggest challenges.
Talks will cover the latest in artificial intelligence, the brain and technology, augmented and virtual reality, space exploration, the future of work, the future of learning, and more.
We’re bringing three full days of live Facebook programming, streaming on Singularity Hub’s Facebook page, complete with 30+ speaker interviews, tours of the EXPO innovation hall, and tech demos. You can also livestream main stage talks at Singularity University’s Facebook page.
Interviews include Peter Diamandis, cofounder and chairman of Singularity University; Sylvia Earle, National Geographic explorer-in-residence; Esther Wojcicki, founder of the Palo Alto High Media Arts Center; Bob Richards, founder and CEO of Moon Express; Matt Oehrlein, cofounder of MegaBots; and Craig Newmark, founder of Craigslist and the Craig Newmark Foundation.
Pascal Finette, SU vice president of startup solutions, and Alison Berman, SU staff writer and digital producer, will host the show, and Lisa Kay Solomon, SU chair of transformational practices, will put on a special daily segment on exponential leadership with thought leaders.
Make sure you don’t miss anything by ‘liking’ the Singularity Hub and Singularity University Facebook pages and turn on notifications from both pages so you know when we go live. And to get a taste of what’s in store, check out the below selection of stories from last year’s event.
Are We at the Edge of a Second Sexual Revolution?By Vanessa Bates Ramirez
“Brace yourself, because according to serial entrepreneur Martin Varsavsky, all our existing beliefs about procreation are about to be shattered again…According to Varsavsky, the second sexual revolution will decouple procreation from sex, because sex will no longer be the best way to make babies.”
VR Pioneer Chris Milk: Virtual Reality Will Mirror Life Like Nothing Else BeforeBy Jason Ganz
“Milk is already a legend in the VR community…But [he] is just getting started. His company Within has plans to help shape the language we use for virtual reality storytelling. Because let’s be clear, VR storytelling is still very much in its infancy. This fact makes it even crazier there are already VR films out there that can inspire and captivate on such a profound level. And we’re only going up from here.”
7 Key Factors Driving the Artificial Intelligence RevolutionBy David Hill
“Jacobstein calmly and optimistically assures that this revolution isn’t going to disrupt humans completely, but usher in a future in which there’s a symbiosis between human and machine intelligence. He highlighted 7 factors driving this revolution.”
Are There Other Intelligent Civilizations Out There? Two Views on the Fermi ParadoxBy Alison Berman
“Cliché or not, when I stare up at the sky, I still wonder if we’re alone in the galaxy. Could there be another technologically advanced civilization out there? During a panel discussion on space exploration at Singularity University’s Global Summit, Jill Tarter, the Bernard M. Oliver chair at the SETI Institute, was asked to explain the Fermi paradox and her position on it. Her answer was pretty brilliant.”
Engineering Will Soon Be ‘More Parenting Than Programming’By Sveta McShane
“In generative design, the user states desired goals and constraints and allows the computer to generate entire designs, iterations and solution sets based on those constraints. It is, in fact, a lot like parents setting boundaries for their children’s activities. The user basically says, ‘Yes, it’s ok to do this, but it’s not ok to do that.’ The resulting solutions are ones you might never have thought of on your own.”
Biohacking Will Let You Connect Your Body to Anything You WantBy Vanessa Bates Ramirez
“How many cyborgs did you see during your morning commute today? I would guess at least five. Did they make you nervous? Probably not; you likely didn’t even realize they were there…[Hannes] Sjoblad said that the cyborgs we see today don’t look like Hollywood prototypes; they’re regular people who have integrated technology into their bodies to improve or monitor some aspect of their health.”
Peter Diamandis: We’ll Radically Extend Our Lives With New TechnologiesBy Jason Dorrier
“[Diamandis] said humans aren’t the longest-lived animals. Other species have multi-hundred-year lifespans. Last year, a study “dating” Greenland sharks found they can live roughly 400 years. Though the technique isn’t perfectly precise, they estimated one shark to be about 392. Its approximate birthday was 1624…Diamandis said he asked himself: If these animals can live centuries—why can’t I?” Continue reading

Posted in Human Robots